Aqueous Curcumin–Sutherlandia Composition for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Curcumin's low solubility and poor bioavailability limit its effectiveness in cancer treatments, and existing formulations face issues with solubility, stability, and safety concerns, while Sutherlandia extracts have limited application in cancer therapy.
Innovation Solution
A composition combining aqueously-soluble extracts of curcumin and Sutherlandia frutescens with an aqueous carrier, optimized through specific extraction and formulation methods, including pH adjustment and solubilizers, for intravenous and oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is extracted using conventional methods, then the extract contains curcumin with potential anticancer activity, but the solubility is low and bioavailability is poor
Solution Approach 1:
The patent uses solubilizing agents (such as cyclodextrins, phospholipids, or surfactants) as intermediaries to enhance the solubility of curcumin in aqueous environments. These mediators form inclusion complexes or micellar structures that encapsulate curcumin, allowing it to dissolve in water-based formulations while maintaining its biological activity.
Solution Approach 2:
The patent modifies physical and chemical parameters of curcumin through processes such as nanoparticle formation, liposomal encapsulation, or chemical derivatization. These parameter changes increase the surface area, alter solubility characteristics, and improve bioavailability without compromising the core anticancer properties of curcumin.
2Reliability
If curcumin is administered at higher doses to improve efficacy, then the therapeutic effect increases, but adverse effects and toxicity increase
Solution Approach 1:
The patent employs targeting ligands, antibodies, or cell-penetrating peptides as intermediaries that direct curcumin specifically to cancer cells. This targeted delivery allows lower overall doses to achieve the same therapeutic effect, reducing systemic toxicity and adverse effects while maintaining anticancer efficacy.
Solution Approach 2:
The patent creates formulations where curcumin is concentrated specifically at the tumor site through passive targeting (EPR effect) or active targeting mechanisms. This local quality enhancement ensures high drug concentration where needed while maintaining low systemic levels, thereby improving the therapeutic index.
3Quantity of substance
If curcumin is formulated with solubilizers and emulsifiers to improve solubility, then the bioavailability increases, but chemical instability and photodegradation occur
Solution Approach 1:
The patent uses nested structural approaches such as liposomes, micelles, or polymeric nanoparticles where curcumin is encapsulated within an protective matrix. This nesting protects curcumin from chemical degradation and photodegradation while maintaining solubility and bioavailability. The outer layer acts as a shield against environmental stressors.
Solution Approach 2:
The patent formulates curcumin in inert or controlled environments such as oxygen-scavenging formulations, antioxidant-containing matrices, or UV-protective encapsulation systems. These inert environments prevent oxidative degradation and photodegradation, maintaining chemical stability while preserving bioavailability.
4Reliability
If Sutherlandia frutescens extract is used alone for cancer treatment, then some anticancer activity is observed, but the efficacy is limited compared to curcumin
Solution Approach 1:
The patent merges curcumin and Sutherlandia frutescens extract into a single formulation, creating a synergistic combination therapy. The components work together through complementary mechanisms: curcumin provides broad-spectrum anticancer activity through multiple pathways, while Sutherlandia frutescens contributes additional anticancer compounds and potentiates curcumin's effects, resulting in enhanced overall efficacy.
Data Source
AI summary
The present invention relates to a composition for use in the treatment of cancer, the composition comprising an aqueously-soluble extract of curcumin and an aqueously-soluble extract of Sutherlandia frutescens. The present invention further relates to the method and use of such a composition in the treatment of cancer.